CHURCH & DWIGHT CO INC /DE/ Q3 FY2026 earnings call

• Strong Execution Amid Headwinds: The company delivered three consecutive quarters of over 5% profitable organic growth despite inflationary pressures from Middle East conflicts and rising global transportation rates.
• Innovation-Led Growth: Innovation remains a core competency, with 26 new innovations across power brands performing well. This includes record shares for Arm & Hammer laundry and litter, and significant share gains for TheraBreath mouthwash.
• Portfolio Optimization: Strategic actions completed in 2025 have focused the portfolio. The company is advancing 2030 growth initiatives, specifically expanding Arm & Hammer, scaling TheraBreath in oral care, and growing international presence.
• International Expansion: International organic sales grew 7.8%, with nine brands achieving double-digit growth. Global e-commerce revenues grew 20%, now representing 25.9% of total consumer sales. Launches in the UK and Australia for Touchland showed excellent early results.
• Brand Performance Highlights:
  • Arm & Hammer: Gained share in value-segment laundry; cat litter consumption grew 5.4%.
  • TheraBreath: Mouthwash reached record 26.8% share; toothpaste building trial with strong ratings.
  • Hero: Acne cleansers launched successfully, outpacing patch category growth.
  • Waterpik: Delivered double-digit sales growth and gained share.
  • Touchland: US growth slowed due to competition in non-competing channels, but distribution expansion plans are on track; international rollout initiated.

The company reported strong performance across its three divisions. US Consumer Business organic sales grew 4.4%, driven by volume growth of 3.6% and favorable price/mix of 0.8%. Key drivers included Arm & Hammer Liquid Laundry Detergent, TheraBreath, and Waterpik. International Consumer Business organic sales increased 7.8%, fueled by 9.1% volume growth, led by TheraBreath, Batiste, Touchland, and OxyClean. Specialty Products Division (SPD) organic sales grew 5%, with 2.9% volume growth and 2.1% favorable price/mix. While specific revenue contribution percentages for each segment are not explicitly stated in the transcript, the broad-based growth across all divisions contributed to overall net sales increases of 1% and organic sales growth of 5.1%.

• Full Year 2026 Organic Sales: Raised to approximately 5% at the high end of the prior range (4%-5%), reflecting strong year-to-date momentum.
• Full Year 2026 Adjusted EPS: Tightened to approximately 7%, down from the prior range of 6%-8%, due to higher inflation assumptions ($150 million impact).
• Full Year 2026 Gross Margin: Expected to expand by approximately 100 basis points, inclusive of cost headwinds.
• Fourth Quarter 2026 Outlook: Organic sales growth expected at approximately 4%; adjusted EPS expected to increase 17%-19% year-over-year.
• Capital Allocation: New $1 billion share repurchase program approved with no expiration date, replacing the prior authorization.

• Inflationary Pressures: Continued inflationary pressure related to the Middle East conflict and rising commodity costs, assumed to be roughly $100/barrel crude oil.
• Transportation Costs: Increasing global transportation rates, viewed as potentially structural in the short term due to driver shortages in the US, though historically transitory.
• Competitive Environment: Elevated promotional levels in categories like laundry and litter, and competitive products impacting Touchland's US growth trajectory.
• Consumer Wallet Pressure: Stretched consumer disposable income due to inflation and gas prices, which may impact consumption patterns.

Q: Analyst asked about innovation in the value tier amidst peer promotions and gross margin outlook for 2027 given inflation. / A: Management emphasized that innovation is a core competency across both household and personal care, focusing on 'good, better, best' strategies. For margins, they expect record productivity in 2027, fixed cost leverage from divestitures, and RGM toolkit usage to offset inflation, maintaining optimism for margin accretion.

Q: Analyst asked about category growth trends and reasons for conservative Q4 guidance despite strong YTD performance. / A: Management noted category growth has stabilized around 2.5%, up from initial 2% estimates. They view the 4% Q4 guidance as conservative but still industry-leading, citing strong October trends and confidence in continued momentum without over-promising.

Q: Analyst asked about pricing strategy, promotional intensity, and hedging levels heading into next year. / A: Management stated that while promotional levels are elevated due to manufacturers spending tariff refunds, elasticities remain strong. They prioritize productivity first, then RGM, and will consider price increases only if inflation becomes structural. Hedging levels are slightly higher than last year but cover only key commodities against a larger inflation bucket.

Q: Analyst asked about the durability of TheraBreath growth and Hero business performance internationally. / A: Management highlighted TheraBreath's long runway due to low household penetration (14%) vs. category (65%) and successful global expansion, including Japan. Hero is gaining share in acne patches and cleansers internationally, with strong consumer reviews and repeat rates driving confidence in its growth trajectory.

Q: Analyst asked about the strategic rationale behind the new $1 billion share buyback authorization. / A: Management characterized the buyback renewal primarily as housekeeping to replace expiring authorizations and maintain capital allocation flexibility. It signals discipline rather than an aggressive shift in M&A or buyback speed, allowing the company to continue investing in the business while returning capital.